Analysis for DHR

$231.50 +6.81 (+3.03%)

📈 Growth — 16/30
💰 Profitability — 18/20
🏦 Financial Health — 19/20
💵 Valuation — 15/20
⚠️ Risk — 5/10

Overall Score: 73/100

Summary:

📈 Growth & Financial Trajectory

Eight quarters show a mixed trend: start Revenues ~$6.54B (2024Q2) and end ~$5.95B (2026Q1), a modest decline (~9%). Net income grew from ~$0.91B to ~$1.03B, a +13% swing, though quarterly results are volatile (notably 2025Q2 dip) before resuming gains.

💰 Margins & Cash Flow

Gross margins run ~58–66% (avg ~60%), with Operating Margin typically in the mid-teens to low-20s. Cash flow from operating activities is broadly positive, peaking in 2026Q1 at about $3.09B; investing/financing cash flows show normalization with occasional quarter-to-quarter swings.

🛡️ Balance Sheet & Liquidity

Assets around $80–83B and Equity around $51–$53B support a conservative balance sheet. Long-term Debt sits ~$16–$18B, with current liabilities ~$6–$8B and Current Ratio generally near 1.8–2.0, indicating solid liquidity.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand shifts; Diagnostics & Life Sciences spend supporting product demand
Risks: Revenue cyclicality and sensitivity to mix; Margin compression or regulatory exposure that could impact cash flow